Rhythm Pharmaceuticals (RYTM) News Today $88.30 +3.07 (+3.60%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$86.20 -2.10 (-2.38%) As of 08/1/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RYTM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Bayforest Capital Ltd Acquires New Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 2 at 3:32 AM | marketbeat.comCanaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM)August 1 at 7:42 AM | insidermonkey.comCanaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM)August 1 at 7:31 AM | msn.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Bought by XTX Topco LtdAugust 1 at 4:04 AM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Recommendation of "Buy" by AnalystsAugust 1 at 3:11 AM | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Rating of "Buy" from AnalystsAugust 1 at 3:10 AM | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 1,520 Shares of StockJuly 30 at 9:05 PM | marketbeat.comRhythm Pharmaceuticals (RYTM) Projected to Post Quarterly Earnings on TuesdayJuly 30 at 8:25 AM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $130,613.60 in StockJuly 30 at 5:46 AM | insidertrades.comFederated Hermes Inc. Increases Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)July 30 at 4:19 AM | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Boosts Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)July 28, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Rating Increased to Hold at Wall Street ZenJuly 26, 2025 | marketbeat.comRhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025July 22, 2025 | globenewswire.comRhythm Pharmaceuticals (NASDAQ:RYTM) Lowered to Sell Rating by Wall Street ZenJuly 19, 2025 | marketbeat.comRhythm Pharmaceuticals CFO Sells 42,120 SharesJuly 18, 2025 | msn.comRhythm Pharmaceuticals (NASDAQ:RYTM) Given New $105.00 Price Target at Canaccord Genuity GroupJuly 18, 2025 | marketbeat.comQ2 Earnings Estimate for RYTM Issued By Leerink PartnrsJuly 16, 2025 | marketbeat.comAnalysts Set Expectations for RYTM Q4 EarningsJuly 15, 2025 | marketbeat.comLeo Wealth LLC Purchases New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)July 14, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Outlook for RYTM EarningsJuly 14, 2025 | marketbeat.comAlps Advisors Inc. Has $2.45 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)July 13, 2025 | marketbeat.comRhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025July 12, 2025 | globenewswire.comRhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It ... - NasdaqJuly 12, 2025 | nasdaq.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 3,817 Shares of StockJuly 12, 2025 | insidertrades.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German Sells 3,817 SharesJuly 11, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $619,828.82 in StockJuly 11, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Pamela J. Cramer Sells 15,572 SharesJuly 11, 2025 | marketbeat.comHunter C. Smith Sells 42,120 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockJuly 11, 2025 | marketbeat.comRhythm Pharma gains as mid-stage trial for rare form of obesity succeedsJuly 11, 2025 | msn.comRhythm Pharmaceuticals (NASDAQ:RYTM) Given New $110.00 Price Target at OppenheimerJuly 10, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Given New $95.00 Price Target at Bank of AmericaJuly 10, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysJuly 10, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common StockJuly 10, 2025 | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Earns Buy Rating from Analysts at The Goldman Sachs GroupJuly 10, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common StockJuly 10, 2025 | gurufocus.comAnalysts Issue Forecasts for RYTM Q2 EarningsJuly 10, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock | ...July 10, 2025 | gurufocus.comRhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common StockJuly 10, 2025 | globenewswire.comRhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo ...July 10, 2025 | finanznachrichten.deRhythm Pharmaceuticals (NASDAQ:RYTM) Sets New 12-Month High After Analyst UpgradeJuly 10, 2025 | marketbeat.comRhythm Pharma Shares Gain on Positive Results From Recent Trial of Obesity TreatmentJuly 9, 2025 | marketwatch.comRhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity - MorningstarJuly 9, 2025 | morningstar.comMRhythm's drug shows promise in study to treat brain damage-related obesityJuly 9, 2025 | reuters.comRhythm Pharmaceuticals Shares Jump Following Promising Phase 2 Data for Obesity DrugJuly 9, 2025 | msn.comRhythm Pharma Surges To Record High On 'Impressive' Results In ObesityJuly 9, 2025 | msn.comRhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockJuly 9, 2025 | globenewswire.comRhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up Following Analyst UpgradeJuly 9, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Needham & Company LLC Analyst SaysJuly 9, 2025 | marketbeat.comRhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic ObesityJuly 9, 2025 | globenewswire.comRhythm Pharmaceuticals (NASDAQ:RYTM) Raised to Strong-Buy at Leerink PartnrsJuly 9, 2025 | marketbeat.com Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Media Mentions By Week RYTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RYTM News Sentiment▼0.780.48▲Average Medical News Sentiment RYTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RYTM Articles This Week▼128▲RYTM Articles Average Week Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Summit Therapeutics News Today Insmed News Today Teva Pharmaceutical Industries News Today Genmab A/S News Today Moderna News Today Dr. Reddy's Laboratories News Today QIAGEN News Today Viatris News Today Ascendis Pharma A/S News Today BridgeBio Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RYTM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
